Current Trends in Lipid-Lowering Target Therapy
| Author | Mahdi Rahmanian | en |
| Author | Alireza Arjangzadeh | en |
| Author | Soorena Khorshidi | en |
| Author | Zahra Rahmanian | en |
| Author | Reza Elmafshar | en |
| Author | Hamed Bazrafshan Drissi | en |
| Orcid | Mahdi Rahmanian [0000-0002-4592-7198] | en |
| Orcid | Alireza Arjangzadeh [0000-0002-7466-7487] | en |
| Orcid | Soorena Khorshidi [0000-0001-9891-9952] | en |
| Orcid | Hamed Bazrafshan Drissi [0000-0002-5705-3504] | en |
| Issued Date | 2026-12-31 | en |
| Abstract | Context: Dyslipidemia is a disorder of lipid metabolism that results in abnormal plasma cholesterol and triglyceride levels. It is a major risk factor for atherosclerotic cardiovascular diseases (ASCVD). Evidence Acquisition: This narrative mini-review included the most relevant articles, without a time restriction. Results: Statins are the first-line pharmacological therapy for dyslipidemia. They reduce low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), triglycerides, and apolipoprotein B, while increasing high-density lipoprotein cholesterol (HDL-C). Ezetimibe is the second most widely used non-statin lipid-lowering agent for lowering LDL-C and is added to statins as combination lipid-lowering therapy in patients with high and extremely high ASCVD risk. Gene-transfer and gene-editing approaches have been introduced for the treatment of certain types of dyslipidemia; however, they remain suboptimal. Conclusions: Statins are first-line medications that should be added to lifestyle modification for the treatment of most dyslipidemias. A combination of statins and ezetimibe is recommended for patients with high and extremely high ASCVD risk. | en |
| DOI | https://doi.org/10.69107/icrj-169719 | en |
| URI | https://brieflands.com/journals/ircrj/articles/169719 | en |
| Keyword | Dyslipidemia | en |
| Keyword | Hypercholesterolemia | en |
| Keyword | Hypertriglyceridemia | en |
| Keyword | Hypolipidemic Agents | en |
| Keyword | Gene Therapy | en |
| Publisher | Brieflands | en |
| Title | Current Trends in Lipid-Lowering Target Therapy | en |
| Type | Review Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ircrj-20-1-169719-publish-pdf.pdf
- Size:
- 173.46 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF